NIH says the FDA has approved Oveporexton for narcolepsy type 1, describing it as the first treatment to restore the neurochemical process controlling alertness and address the condition’s full range of symptoms. The agency says it has funded decades of research on narcolepsy and insomnia, and points to the treatment’s development as an example of why investment in basic brain research matters.